Liverpool researchers uncover how the body’s own chemistry can determine whether antibiotics succeed or fail
New research, published in Nature Communications, provides new insights into how antibiotic resistance develops and could help doctors make better decisions about when and where certain antibiotics should be used, offering fresh insights into the challenge of antimicrobial resistance (AMR).
Researchers from CAMO-Net UK have been investigating the antibiotic combination amoxicillin-clavulanic acid, often known by the brand name Augmentin. It is widely used to treat infections caused by Escherichia coli (E. coli).
The team discovered that some bacterial cells can survive treatment because they already carry hidden resistance mechanisms before antibiotics are even administered. When drug levels are similar to those in the bloodstream, these resistant bacteria can multiply rapidly, leading to treatment failure.
However, the picture changes dramatically in the urinary tract. By recreating the antibiotic concentrations found in blood and urine using an advanced laboratory model, the researchers found that the much higher levels of this antibiotic combination in urine completely eliminated the bacteria, including the resistant sub-populations.
The study also uncovered an unexpected finding. Clavulanic acid, traditionally viewed as a helper agent that protects amoxicillin from bacterial defences, appears to have its own bacteria-killing activity when it reaches the high concentrations found in urine. This additional antibacterial effect may help explain why the combination is particularly effective for UTIs.
Dr Vineet Dubey, lead author of the study from University of Liverpool, said: “We found that antibiotic resistance is not simply something bacteria either have or do not have. Small resistant subpopulations can exist before treatment begins. Whether those bacteria survive depends greatly on the environment they encounter, including the antibiotic concentrations achieved in different parts of the body.”
The findings support current clinical guidance that recommends amoxicillin-clavulanic acid primarily for urinary tract infections caused by E. coli. More broadly, the work highlights the importance of considering where an infection occurs, not just which bacteria are causing it, when selecting antibiotic treatment.
The research also points towards new ways of tackling AMR. Rather than relying solely on developing new antibiotics, scientists may extend the lifespan of existing medicines by understanding how bacteria respond to different environments within the body and by finding ways to prevent resistance from emerging in the first place.
Antimicrobial resistance is considered one of the greatest global health threats of the 21st century, contributing to millions of deaths worldwide each year. By revealing how drug concentrations within the body influence bacterial evolution, the Liverpool team’s work provides an important step toward preserving the effectiveness of existing antibiotics and improving patient care.
The study, Molecular pharmacodynamics of amoxicillin-clavulanic acid for urinary tract infections caused by Escherichia coli, was led by researchers at the University of Liverpool, Liverpool Clinical Laboratories and CAMO-Net UK.
